primary hepatocellular carcinoma
Conditions
Interventions
Case series:combined treatment of apatinib with radiotherapy
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. aged at least 18 years old; 2. pathologically diagnosed as primary hepatocellular carcinoma, confirmed by CT and pathology. 3. of patients were treated with primary radiotherapy, without any anti-tumor therapy before radiotherapy and with complete clinical and pathological data; 4. ECOG score 0-2 points; 5. more than the expected survival time in March; 6. subjects received other treatment or surgical damage has been restored over 4 weeks, and the wound has healed completely; 7. adequate bone marrow, liver and kidney function, cardiac function, tolerance, radiotherapy and chemotherapy; 8. the main organs function properly, that is, the following standards: (1) routine blood test standards should be consistent (within 14 days without blood transfusion and blood products, not using G-CSF and other hematopoietic stimulating factors to correct): HB = 90 g/L; ANC = 1.5 * 10^9/L; PLT = 80 * 10^9/L; (2) biochemical examination should meet the following standards: TBIL 45 ml/min C. = 1.25 ULN long serum Cr or endogenous (Cockcroft-Gault formula); 9. women of childbearing age must have taken reliable contraception or pregnancy test in 7 days before entering the group (in serum or urine), and the results were negative, and willing to contraception during the study period and the last 8 weeks after giving drug test using appropriate. For men, consent should be given to the appropriate method of contraception or surgical sterilization 8 weeks after the trial and at the end of the test; 10. subjects volunteered to join the study, and signed informed consent, good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. confirmed of apatinib and / or its accessories allergy; 2. with high blood pressure and the antihypertensive drug treatment can not be reduced to the normal range (>140 systolic blood pressure mmHg, diastolic blood pressure >90 mmHg), with I level above grade I coronary heart disease, arrhythmia (including QTc prolongation > 450 male MS, female MS > 470) and grade I heart function insufficiency; patients with positive urinary protein; 3. there are a variety of factors that affect oral medication (such as inability to swallow, nausea, vomiting, chronic diarrhea, and intestinal obstruction); 4. with a clear bleeding tendency of patients, including the following: local active ulcerative lesions, and fecal occult blood (+ +) can not be enrolled; 2 months melena, hematemesis history; 5. coagulation dysfunction (INR>1.5, APTT>1.5, ULN), with bleeding tendency; 6. pregnant or lactating women; 7. received any radiation therapy before; 8. there are internal and external medical diseases and psychiatric diseases, which are not suitable for chemotherapy and radiotherapy; 9. have acute infection, need antibiotic treatment person; 10. patients who participated in other clinical trials within four weeks; 11. according to the researcher's judgment, there are patients who seriously endanger the safety of patients or affect the patients who complete the study; 12., the researchers considered unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS (Progression-Free Survival); | — |
Countries
China
Contacts
Public ContactChen Yongshun
Renmin Hospital of Wuhan University Department of oncology IV
Outcome results
None listed